Playback speed
10 seconds
ESMO Asia 2023 Insights: "Lenvatinib vs. Sorafenib 2L Therapy in HCC Patients Progressed to Atezolizumab + Bevacizumab"
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Mara Persano
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Mara Persano
71 views
January 17, 2024
Comments 0
Login to view comments.
Click here to Login